37.38EUR-0.48%Mkt Cap: —P/E: —1d ago
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous …
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
Key Statistics
Company
Market Cap—
Enterprise Value2.08B $
Revenue (TTM)35.43M $
Gross Profit35.43M $
Net Income (TTM)-26.04M $
Revenue/Share0.7413 USD
Last Price37.38 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees100
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-182.28
EV/Revenue58.66
P/S—
P/B-22.13
EPS (TTM)-1.35
EPS (Forward)—
52W Range
34.2055% of range39.98
52W High39.98 EUR
52W Low34.20 EUR
Profitability
Gross Margin100.00%
Oper. Margin-196.42%
EBITDA Margin-32.18%
Profit Margin-73.52%
ROE—
ROA-10.06%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.33M $
CapEx (TTM)—
FCF Margin-24.22%
FCF Yield—
Net Debt46.27M $
Net Debt/EBITDA-4.06
Balance Sheet
Debt/Equity—
Current Ratio1.09
Quick Ratio1.05
Book Value/Sh-1.7460 EUR
Cash/Share1.090 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.19.61M
Float31.95M
Insiders15.55%
Institutions36.13%
Technical
SMA 506.677 (+459.8%)
SMA 2006.545 (+471.1%)
Beta0.57
S&P 52W Chg18.16%
Avg Vol (30d)18.09K
Avg Vol (10d)1.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—